Acute Mountain Sickness
41
0
1
32
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
2.4%
1 terminated out of 41 trials
97.0%
+10.4% vs benchmark
27%
11 trials in Phase 3/4
9%
3 of 32 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 32 completed trials
Clinical Trials (41)
Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness
HighCycle Study: Effect of High Altitude on Acute Mountain Sickness in Women Related to Their Menstrual Cycle Phase
HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men
Voluntary Isocapnic Hyperpnea in Hypoxia to Mitigate Acute Mountain Sickness
CO2 Supplement for Treatment of Acute Mountain Sickness
Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness
EleVation carE: a Randomized Controlled Trial on the Prevention of Acute Mountain Sickness With Suxiao Jiuxin Pill
Risk Factors Associated With High Altitude Sickness: A Case-Control Study
Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness
The Effect of Continuous Positive Pressure Ventilation on Symptoms of Acute Mountain Sickness
Effect of Inhalation of Low Dose CO2 on Exercise Performance at High Altitude
The Effects of Intermittent Hypoxia on Acute Hypoxic Injury
Colorado-Oregon Altitude Study
Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude
Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide
Decompression Tables for Diving at Altitude
Alternative Treatments in Acute Mountain Sickness
Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years
Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness
Sickness Evaluation at Altitude With Acetazolamide at Relative Doses